Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/179772
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Portell Buj, Elena | - |
dc.contributor.author | Bonet Rossinyol, Queralt | - |
dc.contributor.author | López Gavín, Alexandre | - |
dc.contributor.author | Roman, Angely | - |
dc.contributor.author | Fernández Pittol, Mariana José | - |
dc.contributor.author | Tudó i Vilanova, Griselda | - |
dc.contributor.author | González Martín, Julián | - |
dc.date.accessioned | 2021-08-30T12:05:19Z | - |
dc.date.available | 2021-08-30T12:05:19Z | - |
dc.date.issued | 2021-01-08 | - |
dc.identifier.issn | 0021-8820 | - |
dc.identifier.uri | http://hdl.handle.net/2445/179772 | - |
dc.description.abstract | Nontuberculous mycobacteria include 198 mycobacterial species. Among these, Mycobacteroides abscessus is a rapidly growing mycobacteria that causes lung and skin infections. M. abscessus lung infections are difficult to treat due to the high levels of resistance to several classes of antibiotics. The current treatment is based on combining at least two or three antibiotics. However, treatment outcomes remain very poor. The objective was to compare the in vitro activity of amikacin, tigecycline, imipenem, and clarithromycin, alone and in two different three-drug combinations (amikacin/tigecycline/imipenem and amikacin/tigecycline/clarithromycin) against seven M. abscessus subsp. abscessus clinical isolates using the time-kill assay. The two combinations showed greater activity than the antibiotics tested individually. Even though both combinations showed similar activity as well as no antagonistic activity, the combination including imipenem could not be an alternative treatment against M. abscessus subsp. abscessus lung infections caused by clarithromycin susceptible isolates. However, this combination could be considered against clarithromycin resistant isolates. Future studies are necessary to confirm this hypothesis. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Springer Nature | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1038/s41429-020-00392-0 | - |
dc.relation.ispartof | Journal of Antibiotics, 2021, vol. 74, p. 285-290 | - |
dc.relation.uri | https://doi.org/10.1038/s41429-020-00392-0 | - |
dc.rights | cc-by (c) Portell Buj, Elena et al., 2021 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Fonaments Clínics) | - |
dc.subject.classification | Malalties del pulmó | - |
dc.subject.classification | Farmacologia respiratòria | - |
dc.subject.other | Pulmonary diseases | - |
dc.subject.other | Pulmonary pharmacology | - |
dc.title | Comparison of two-drug combinations, amikacin/tigecycline/imipenem and amikacin/tigecycline/clarithromycin against Mycobacteroides abscessus subsp. abscessus using the in vitro time-kill assay | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 707171 | - |
dc.date.updated | 2021-08-30T12:05:19Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33420382 | - |
Appears in Collections: | Articles publicats en revistes (Fonaments Clínics) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
707171.pdf | 448.03 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License